Juventas Therapeutics Receives $22,200,000 Series B Financing
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d95845e0-35b5-4ef6-9448-0ed2bca4b1b2&Preview=1
Date 7/17/2012
Company Name Juventas Therapeutics
Mailing Address 10000 Cedar Ave. Cleveland, OH 44106
Company Description Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. The company’s lead product, Stromal–cell Derived Factor 1 (SDF–1), has been shown to protect and repair tissue following organ–damage in a broad range of pre–clinical disease models.
Proceeds Purposes The proceeds will fund completion of ongoing Phase II clinical trials investigating the use of JVS-100 in treating patients with chronic heart failure or critical limb ischemia.
M&A Terms
Venture Investor Triathlon Medical Ventures
Venture Investor Fletcher Spaght Ventures
Venture Investor Reservoir Venture Partners
Venture Investor Early Stage Partners
Venture Investor Takeda Ventures
Venture Investor Venture Investors
Venture Investor Glengary
Venture Investor Tri-State Investment Group
Venture Investor Global Cardiovascular Innovation Center